MLTX Financials
Moonlake Immunotherapeutics - Financial statements & key metrics
Stock Price
$16.33
Market Cap
$1.16B
EPS
$-3.33
Income Statement Highlights
Most Recent Quarter: 2024-12-31
Revenue
$0.00
Gross Profit
$-1.38M
Operating Income
$-143.09M
Net Income
$-118.94M
EPS (Diluted)
$-
Balance Sheet Highlights
Total Assets
$477.93M
Total Liabilities
$24.54M
Shareholders Equity
$446.83M
Cash & Equivalents
$180.43M
Total Debt
-
Cash Flow Highlights
Operating Cash Flow
$-116.59M
CapEx
$519520
Free Cash Flow
$-117.11M
Profitability Metrics
ROE
-0.5%
View Complete Financial Statements
Full income statements, balance sheets, and cash flows for multiple periods
Open Full FinancialsFrequently Asked Questions
What is MLTX revenue?
MLTX's most recent quarterly revenue was $0.00. Annual revenue can be calculated by summing the four most recent quarters.
Is MLTX profitable?
MLTX reported a loss of $118.94M in the most recent quarter.
What is MLTX market cap?
MLTX has a market capitalization of $1.16B, making it a small-cap stock.
Does MLTX have debt?
View MLTX's balance sheet for debt information.
What is MLTX cash flow?
MLTX's most recent quarterly free cash flow was $-117.11M.